We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accelerate Diagnostics, Inc. (AXDX - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because AXDX is now in overbought territory with an RSI value of 74.27.
What is RSI?
RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.
Other Factors
Yet AXDX’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in Accelerate Diagnostics’ stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of AXDX’s prospects for the near term.
Over the past two months, investors have witnessed 2 earnings estimate revisions lower compared to none higher for the current year. The consensus estimate for AXDX has also been on a downward trend over the same time period too, as the estimate has fallen from -$1.26/share two months ago to just -$1.33/share today.
If this wasn’t enough, Accelerate Diagnostics also has a Zacks Rank #4 (Sell)which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Accelerate Diagnostics (AXDX) Enters Overbought Territory
Accelerate Diagnostics, Inc. (AXDX - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because AXDX is now in overbought territory with an RSI value of 74.27.
What is RSI?
RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.
Other Factors
Yet AXDX’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in Accelerate Diagnostics’ stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of AXDX’s prospects for the near term.
Over the past two months, investors have witnessed 2 earnings estimate revisions lower compared to none higher for the current year. The consensus estimate for AXDX has also been on a downward trend over the same time period too, as the estimate has fallen from -$1.26/share two months ago to just -$1.33/share today.
If this wasn’t enough, Accelerate Diagnostics also has a Zacks Rank #4 (Sell)which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>